Fresenius Medical's 15min chart shows MACD Death Cross, Bearish Marubozu signal.

Based on the technical analysis of Fresenius Medical's 15-minute chart, the MACD Death Cross and Bearish Marubozu indicators have triggered at 08/13/2025 13:00, suggesting that the stock price is poised to continue its downward trend. This suggests that sellers are in control of the market, and bearish momentum is likely to persist.

Fresenius Medical Care AG (FME) reported robust earnings for the quarter ended June 30, 2025, with adjusted earnings per share (EPS) of 47 cents, a 28.6% increase from the same period last year. Revenue rose by 0.5% to €4.79 billion, slightly below analyst expectations [1]. Despite these positive financials, technical indicators have raised concerns about the stock's near-term performance.

On August 8, 2025, Fresenius Medical Care AG's 15-minute chart triggered a MACD Death Cross, accompanied by a Bearish Marubozu pattern at 14:45. This signals a potential continuation of the stock's downward trend, with sellers dominating the market and bearish momentum likely to persist [1]. The mean earnings estimate of analysts has fallen by about 2.1% in the last three months, and the current average analyst rating on the shares is "hold." The breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold," and 2 "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is "buy." Wall Street's median 12-month price target for Fresenius Medical Care AG is $30.00, about 16.9% above its last closing price of $24.94 [1].

Adding to the bearish sentiment, Fresenius Medical announced the launch of a EUR 1 billion share buyback program, with the first tranche valued at up to EUR 600 million. The buyback program, announced as part of the company's new capital allocation framework, is scheduled for completion no later than April 30, 2026. The share buyback program marks a swift implementation of a key element supporting the company's new FME Reignite strategy. However, the market reaction to the buyback announcement was mixed, with the stock trading 0.15% lower at $24.05 on the New York Stock Exchange and 0.39% higher at EUR 41.31 on the XETRA [2].

References:
[1] Reuters. (2025). Fresenius Medical Care AG Reports Results for the Quarter Ended June 30. Retrieved from https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TX2BV:0-fresenius-medical-care-ag-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[2] RTTNews. (2025). Fresenius Medical Care AG Launches EUR 600 Million First Tranche EUR 1 Billion Share Buyback. Retrieved from https://www.nasdaq.com/articles/fresenius-medical-launches-eur-600-mln-first-tranche-eur-1-bln-share-buyback